LongevityNext
ER-100 has sponsor-reported first dosing, while other programmes remain at different stages. Trial entry, human-cell findings and clinical benefit are not equivalent.
What NewLimit’s disclosed Series C and development updates show about company building, without inferring valuation, investor motives or clinical success.
A current-evidence framework separating digital-twin forecasts, aging measures and AI-enabled drug discovery from clinical utility and platform claims.
Diagnostics, canine therapeutics and human-drug discovery face different operating and regulatory tests. Dated examples clarify the distinctions.
US labeling and advertising frameworks address different questions. Product category, implied meaning and evidence must be assessed together.
Reviews what current DoH, UAE and ADGM official sources document about Abu Dhabi’s healthy-longevity clinic landscape.
Compares molecular, organ-level, functional and clinical aging measures by intended use, validation and limits.
Separates DO-HEALTH's null primary clinical endpoint family from a later small post hoc DNA-methylation signal.
Tracks human senolytic evidence, registered programs, negative translation and preclinical limits.
Maps inflammaging definitions, human measures, outcome associations, mechanisms and intervention limits.